邁博藥業-B(02181.HK)：已向國家知識產權局提交CMAB020發明專利申請
格隆匯3月24日丨邁博藥業-B(02181.HK)宣佈，公司已經於2020年3月23日向中國國家知識產權局提交重組雙功能抗體融合蛋白的發明專利申請(專利申請號：202010208906.8/PCT號：PCT/CN2020/080859)("CMAB020")。CMAB020有望應用於預防和治療SARS-CoV/-2(SARS-CoV及SARS-CoV-2)感染和SARS/COVID-19疾病(SARS-CoV/-2所導致的肺炎)。公司已經完成CMAB020實驗規模的蛋白製備以及體外功能評估，並即將啟動體內實驗以對CMAB020進行進一步的技術評估。
CMAB020為專有的雙功能融合蛋白，預期用於預防及治療SARS-CoV/-2(SARS-CoV及SARS-CoV-2)感染及SARS/COVID-19疾病。CMAB020具有兩個功能臂：(1)一個功能臂為高親和力靶向SARS-CoV、SARS-CoV-2及其他SARS樣冠狀病毒S蛋白的全人源單抗("Ab")；(2)另一功能臂為截短的血管緊張素轉化酶2("ACE2")蛋白。Ab和ACE2與S蛋白結合表位不同。截短的ACE2保留了將血管緊張素II轉化為血管緊張素1-7的酶活性，從而降低感染肺部的血管收縮，增加血液灌注。CMAB020有望起到保護器官的作用並減輕COVID-19引發嚴重急性呼吸窘迫綜合症。除此以外，CMAB020還可以拮抗受體結合域與CD147的結合，減輕肺部炎症及細胞因子風暴。
yu 2020年3月24日，Mabpharm (HK) Limited，公司的全資子公司，與在美國納斯達克上市的Sorrento簽訂了獨家授權合約。根據該協定，公司授予Sorrento於北美和歐洲開發和商業化CMAB020的獨家永久許可。Sorrento是一家以抗體為中心的臨牀階段生物製藥公司，致力於開發新的治療方法，將惡性腫瘤轉化為可控制且可能治癒的疾病。Sorrento擁有一系列創新和協同的資產，如廣泛的全人類抗體庫("G-MAB™")，臨牀期嵌合抗原受體T細胞("CAR-T")，細胞內靶向抗體("iTAbs")，抗體藥物結合物("ADC")和溶瘤病毒("Sephrehvir®")。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
